Abstract

Recognition of TP53’s prominent role in protection from cancer has boosted a huge amount of scientific reports (around 40000) describing the function of TP53 as a tumour suppressor. Quite an unusual feature of a tumour suppressor was noted – TP53 is point mutated rather than inactivated in cancers and is highly expressed in tumours. Mutation of TP53 gene confers novel oncogenic properties on TP53 protein.

• 1.   Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004.2:281-97.
• 2.   Bastien R, Lewis TB, Hawkes JE, et al. Highthroughput amplicon scanning of the TP53 gene in breast cancer using highresolution fluorescent melting curve analyses and automatic mutation calling. Hum Mutat. 2008;5:757–64.
• 3.   Beckman G, Birgander R, Sjalander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994;44:266–70.
• 4.   Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;1:107–20.
• 5.   Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. P53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005;19(18):2122–37.
• 6.   Candeias, M. M. et al. p53 mRNA controls p53 activity by managing Mdm2 functions. Nature Cell Biol. 2008;10:1098–1105.
• 7.   Chan WM, Siu WY, Lau A, Poon RY. How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol. 2004;8:3536–51.
• 8.   Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;5:745–52.
• 9.   Chene P. In vitro analysis of the dominant negative effect of p53 mutants. J M Biol. 1998;2:205–09.
• 10.   Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992;5043:459–62.
• 11.   Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ. 2006;6:994–1002.
• 12.   Costa, S. et al. Importance of TP53codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008;8:32.
• 13.   Crighton D, Wilkinson S, Ryan KM. DRAM links autophagy to p53 and programmed cell death. Autophagy. 2007;1:72–74.
• 14.   De Oliveira WR, Rady PL, Grady J, et al. Association of p53 arginine polymorphism with skin cancer. Int J Dermatol. 2004;43:489–493.
• 15.   DeLeo AB, Jay G, Appella E, et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. PNAS, USA. 1979;5:2420–24.
• 16.   Dumont P, Leu JI, Della Pietra A III, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357 65.
• 17.   El-Deiry WS, Harper JW, O’Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;5:1169–74.
• 18.   Eliyahu D, Michalovitz D, Eliyahu S, et al. Wildtype p53 can inhibit oncogene-mediated focus formation. PNAS, USA. 1989;22:8763–67.
• 19.   Eliyahu D, Raz A, Gruss P, et al. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature. 1984;5995:646–49.
• 20.   Felley-Bosco E, Weston A, Cawley HM, et al. unctional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am. J. Hum. Genet. 1993;53:752–59.
• 21.   Finlay CA, Hinds PW, Tan TH, et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988;2:531–39.
• 22.   Flores ER, Tsai KY, Crowley D, et al. (2002). p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 6880:560–64.
• 23.   Frazer KA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851–61.
• 24.   Gatz SA & Wiesmuller L. p53 in recombination and repair. Cell Death Differ. 2006;6:1003–16.
• 25.   Gemignani F, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004;23:1954–56.
• 26.   Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol. 2004;18:7987–97.
• 27.   Godar S, Ince TA, Bell GW, Feldser D, et al. Growth inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell. 2008;1:62–73.
• 28.   Gottlieb E, Haffner R, von Ruden T, et al. Downregulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J. 1994;6:1368–74.
• 29.   Gu W & Roeder RG. Activation of p53 sequencespecific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997;4:595–606.
• 30.   Hollstein M, Sidransky D, Vogelstein B, et al. P53 mutations in human cancers. Science. 1991;253: 49–5.
• 31.   Jones JS, Chi X, Gu X, et al. Modifiers of expression in mutations of mismatch repair gene carriers in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:5845–5849.
• 32.   Kanaya T, Kyo S, Hamada K, Takakura M, et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res. 2000;6(4):1239–47.
• 33.   Kato S, et al. Understanding the functionstructure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. PNAS, USA. 2003;100: 8424–29.
• 34.   Koushik A, Platt RW, Franco EL. Cancer Epidemiol Biomarkers Prev, 2004;13:11–22. Review.
• 35.   Kruse JP & Gu W. SnapShot: p53 posttranslational modifications. Cell. 2008;133: 930–31.
• 36.   Kurihara A, et al. Ser46 phosphorylation of p53 is not always sufficient to induce apoptosis: multiple mechanisms of regulation of p53-dependent. Genes Cells. 2007 Jul;12(7):853-61.
• 37.   Lanyi A, Deb D, Seymour RC, et al. Gain of function’ phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene. 1998;16(24):3169–76.
• 38.   Lazar V, et al. Simple sequence repeats polymorphism within the p53 gene.Oncogene. 1993;8:1703–05.
• 39.   Le Cam L, Linares LK, Paul C, Julien E, et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell. 2006;4:775–88.
• 40.   Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003;6:779–91.
• 41.   Leu JI, Dumont P, Hafey M, Murphy ME, et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004;6:443e50.
• 42.   Li Y & Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene. 2007;26:2220–25.
• 43.   Lin J, Teresky AK, Levine AJ. Two critical hydrophobic amino acids in the Nterminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene. 1995;12:2387–90.
• 44.   Linzer DI & Levine AJ. Characterization of a 54K Dalton cellular SV40 tumour antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979;17:43–52.
• 45.   Ludwig RL, Bates S, Vousden KH et al. Differential activation of target cellular Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1996;280 (1998) 1614–1617.
• 46.   Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science.1990;4985:1233–38.
• 47.   Marin MC, Jost CA, Brooks LA, Irwin MS, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000;25:47e54.
• 48.   Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis. 2003;18:377–85.
• 49.   Matlashewski GJ, Tuck S, Pim D, et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7:961–963.
• 50.   Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science. 2006;312(5780):1650–53.
• 51.   Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell.1991;65(5):765–74.
• 52.   Murphy M, Ahn J, Walker KK, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 1999;13:2490–501.
• 53.   Murray-Zmijewski F, Lane DP, et al. P53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006;13:962–72.
• 54.   Murray-Zmijewski F, Slee EA, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol. 2008;9(9):702–12.
• 55.   Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7(3):683–94.
• 56.   Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288(5468):1053–58.
• 57.   Ohayon T, Gershoni-Baruch R, Papa MZ, et al. The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer. 2005;92:1144–8.
• 58.   Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of LiFraumeni syndrome. Cell. 2004;119(6):847–60.
• 59.   Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63:6643–50.
• 60.   Oren M & Levine AJ. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. PNAS, USA. 1983;80(1):56–9.
• 61.   Petitjean A, Achatz MI, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157–65.
• 62.   Pim D, Banks L. p53 polymorphic variants at codon 72 exerts different effects on cell cycle progression. Int J Cancer 2004;108:196-9.
• 63.   Pim D, Banks L. promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol. 2004;9:4952–60.
• 64.   Resnick MA & Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl AcadSci U S A. 2003;100(17):9934–39.
• 65.   Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 1997;15:887–98.
• 66.   Shen H, Solari A, Wang X, et al. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep. 2004;11:1115–20.
• 67.   Sjalander A, Birgander R, Athlin L, et al. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis. 1995;16:1461e4.
• 68.   Sjalander A, Birgander R, Saha N, et al. p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered. 1996;46:41–48.
• 69.   Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 2007;9(5):573–80.
• 70.   Sourvinos G, Kazanis I, Delakas D, et al. Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumor suppressor genes. J. Urol. 2001;165:249e52.
• 71.   Soussi T &Wiman KG. Shaping genetic alterationsin human cancer: the p53 mutation paradigm. Cancer Cell. 2007;12(4):303–12.
• 72.   Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229–234.
• 73.   Taira N, Nihira K, Yamaguchi T, Miki Y. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage.Mol Cell. 2007;25:725–38.
• 74.   Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989;246(4929):491–94.
• 75.   Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53- dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404(6773):42–9.
• 76.   Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell. 2006;24(6):827–39.
• 77.   Teodoro JG, Parker AE, Zhu X, et al. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science.2006;313(5789):968–71.
• 78.   Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–100.
• 79.   Unger T, Mietz JA, Scheffner M, et al. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol. 1993;13(9):5186–94.
• 80.   Vikhanskaya F, Siddique MM, Kei Lee M, et al. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res 2005;11:4348–56.
• 81.   Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–10.
• 82.   Vousden KH & Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8(4):275–83.
• 83.   Willis A, Jung EJ, Wakefield T. Mutant p53 exerts a dominant negative effect by preventing wildtype p53 from binding to the promoter of its target genes. Oncogene. 2004;23:2330–38.
• 84.   Wolf D, Harris N, Rotter V. Reconstitution of p53 expression in a nonproducer Ab-MuLVtransformed cell line by transfection of a functional p53 gene. Cell. 1984;38(1):119–26.
• 85.   Wu X, Bayle JH, Olson D, Levine AJ. The p53- mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7(7A):1126–32.
• 86.   Xu Y, Yao L, Ouyang T, et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res. 2005;11:7328–7333.
• 87.   Yin Y, Stephen CW, Luciani MG, et al. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol. 2002;4:462–67.
• 88.   Zakut-Houri R, Bienz-Tadmor B, Givol D, et al. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J. 1985;4:1251–55.
• 89.   Zalcenstein A, Weisz L, Stambolsky P, et al. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.Oncogene. 2006;25:359–69.
• 90.   Zhang JH, Li Y, Wang R, et al. p53 gene polymorphism with susceptibility to esophageal cancer . Zhonghua Zhong Liu ZaZhi. 2003;25:365–367.

Data Sharing Statement

Funding